Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2 Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
Portfolio Pulse from Benzinga Newsdesk
Biodesix, Inc. (NASDAQ:BDSX) announced that the ORACLE study, evaluating the performance of the Nodify XL2® Test, achieved its primary endpoint of a significant change in the management of benign lung nodules. The data was published in PLOS ONE.
July 12, 2023 | 10:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The successful ORACLE study results for Biodesix's Nodify XL2® Test could potentially boost the company's reputation and demand for its diagnostic solutions.
The successful completion of the ORACLE study and the achievement of its primary endpoint could potentially increase the demand for Biodesix's Nodify XL2® Test. This could lead to increased revenues for the company, which could positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100